AR078159A1 - Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica. - Google Patents

Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.

Info

Publication number
AR078159A1
AR078159A1 ARP100103257A ARP100103257A AR078159A1 AR 078159 A1 AR078159 A1 AR 078159A1 AR P100103257 A ARP100103257 A AR P100103257A AR P100103257 A ARP100103257 A AR P100103257A AR 078159 A1 AR078159 A1 AR 078159A1
Authority
AR
Argentina
Prior art keywords
ultra
micronized
etanolamide
palmitoil
composition containing
Prior art date
Application number
ARP100103257A
Other languages
English (en)
Original Assignee
Epitech Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42211652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078159(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epitech Group Srl filed Critical Epitech Group Srl
Publication of AR078159A1 publication Critical patent/AR078159A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica para uso humano o veterinario, que contiene una cantidad con eficacia terapéutica de palmitoil-etanolamida en forma ultra-micronizada, donde más del 90% en peso de palmitoil-etanolamida tiene tamanos de partículas menores que 6 micrones, en conjunto con excipientes farmacéuticamente aceptables. Reivindicacion 8: La composicion segun cualquiera de las reivindicaciones 1 a 7, donde dicha palmitoil-etanolamida está en combinacion con un compuesto antioxidante. Reivindicacion 9: La composicion segun la reivindicacion 8, donde dicho antioxidante se selecciona entre queracetina, resveratrol, polidatina, luteolina, tocoferol, y ácido tioctico.
ARP100103257A 2009-09-07 2010-09-06 Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica. AR078159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2009/000399 WO2011027373A1 (en) 2009-09-07 2009-09-07 Composition containing ultra-micronized palmitoyl - ethanolamide

Publications (1)

Publication Number Publication Date
AR078159A1 true AR078159A1 (es) 2011-10-19

Family

ID=42211652

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103257A AR078159A1 (es) 2009-09-07 2010-09-06 Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
ARP190102266A AR115939A2 (es) 2009-09-07 2019-08-09 Composición que contiene palmitoil-etanolamida ultra-micronizada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190102266A AR115939A2 (es) 2009-09-07 2019-08-09 Composición que contiene palmitoil-etanolamida ultra-micronizada

Country Status (14)

Country Link
US (2) US8470373B2 (es)
EP (2) EP2475352B2 (es)
JP (1) JP5746178B2 (es)
KR (1) KR101662871B1 (es)
CN (2) CN102186459A (es)
AR (2) AR078159A1 (es)
AU (1) AU2009352080B2 (es)
BR (1) BRPI0919753B8 (es)
CA (1) CA2738117C (es)
CY (2) CY1116698T1 (es)
ES (2) ES2548190T3 (es)
PL (2) PL2796129T3 (es)
PT (2) PT2796129E (es)
WO (1) WO2011027373A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109973A2 (en) 2008-03-04 2009-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds and methods of treating obesity
CA2738117C (en) 2009-09-07 2016-12-06 Epitech Group S.R.L. Composition containing ultra-micronized palmitoyl-ethanolamide
US20150202179A1 (en) * 2012-07-20 2015-07-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Fatty acid derivatives for use in a method of treating depression and associated conditions
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
EP2921167B1 (en) 2014-03-19 2016-08-17 EPITECH GROUP S.p.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
ES2772252T3 (es) * 2014-03-21 2020-07-07 Epitech Group S P A Preparaciones oftálmicas, intraarticulares o intravesicales que contienen N-acil-etanolaminas
DK2944309T3 (da) * 2014-05-14 2019-06-03 Epitech Group S P A Anvendelse af palmitoylethanolamid i kombination med opioider
PL2965765T3 (pl) 2014-07-08 2019-11-29 Epitech Group S P A Zastosowanie adelmidrolu w leczeniu dysfunkcji nabłonka
EP2985037B1 (en) 2014-08-13 2017-06-21 EPITECH GROUP S.p.A. A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine
JP2015155412A (ja) * 2015-03-03 2015-08-27 エピテック・グループ・エス．アール．エル． 超微粉化パルミトイル−エタノールアミドを含む組成物
NL2014464B1 (en) 2015-03-16 2017-01-13 Vanderbilt Science Holding Ltd Composition for use in the treatment of neuropathic pain.
US11234956B2 (en) * 2015-04-29 2022-02-01 SciSparc Ltd. Combination of cannabinoids and n-acylethanolamines
WO2016183134A1 (en) * 2015-05-12 2016-11-17 Cutting Edge Medical Solutions, Llc Palmitoylethanolamide compositions
ITUB20153066A1 (it) * 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea
RU2737893C2 (ru) 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
ITUB20154849A1 (it) * 2015-10-30 2017-04-30 Epitech Group S P A ADELMIDROL PER L'USO NELLE PATOLOGIE CARATTERIZZATE DA INSUFFICIENTE AGONISMO DEL RECETTORE PPAR-gamma
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.
NL2017559B1 (en) * 2016-09-30 2018-04-10 Vanderbilt Science Holding Ltd Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles
CN106478445A (zh) * 2016-11-07 2017-03-08 华中药业股份有限公司 一种非那西丁微粉的制备方法
EP3417846A1 (en) 2017-06-19 2018-12-26 Gifar Srl Food and/or nutraceutical composition
IT201700068608A1 (it) * 2017-06-20 2018-12-20 Neilos S R L Composizione per trattamento o prevenzione di una malattia neurodegenerativa
SG10201802129QA (en) * 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
IT201800003912A1 (it) * 2018-03-26 2019-09-26 Innovet Italia Srl N-palmitoil-d-glucosamina in forma micronizzata
IT201800004439A1 (it) * 2018-04-12 2019-10-12 ASSOCIAZIONE DI CURCUMA (Curcuma longa L.), PALMITOILETANOLAMIDE (PEA) E L-TRIPTOFANO
US12036193B2 (en) 2019-09-15 2024-07-16 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for treating neurological disorders
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
US11684600B2 (en) * 2020-03-04 2023-06-27 Compact Disc Incorporated Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
IT202000007831A1 (it) 2020-04-14 2021-10-14 Epitech Group S P A Adelmidrol per l’uso nel trattamento della fibrosi polmonare
GR20200100479A (el) * 2020-08-13 2022-03-09 Pharma Unimedis Ike, Συμπληρωμα διατροφης για την προληψη και/ή τη θεραπεια του πονου και/ή νευροπαθειων
WO2022141821A1 (zh) * 2020-12-29 2022-07-07 汉义生物科技（北京）有限公司 一种大麻素泡腾制剂及其制备方法
IT202100006494A1 (it) * 2021-03-18 2022-09-18 Epitech Group S P A N-palmitoil-etanolamide per l’uso nella prevenzione del carcinoma colo-rettale
IT202100015278A1 (it) 2021-06-11 2022-12-11 Epitech Group S P A Composizione di n-palmitoil-etanolamide e baicaleina in forma comicronizzata
IT202100024464A1 (it) * 2021-09-23 2023-03-23 Epitech Group S P A N-palmitoil-etanolamide e acido docosaesaenoico per l’uso nel trattamento del disturbo dello spettro autistico e di altre sindromi depressive
WO2023133555A2 (en) * 2022-01-10 2023-07-13 Zilker Sciences Llc Palmitoylethanolamide treatment for covid-19-related inflammation
IT202200011957A1 (it) * 2022-06-07 2023-12-07 Erbozeta S P A Associazione tra PEA e melatonina per il trattamento di dolore e infiammazione
IT202200017820A1 (it) * 2022-08-30 2024-03-01 Unifarco S P A Compressa nutraceutica comprendente palmitoiletanolamide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
WO1989011335A1 (en) 1988-05-17 1989-11-30 Liposome Technology, Inc. Preparation of uniform-size liposomes and other lipid structures
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
US5679667A (en) † 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
WO1994028876A1 (en) 1993-06-07 1994-12-22 Advanced Therapies, Inc. Liposome powders
US5622715A (en) 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
IT1271266B (it) 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
IT1302264B1 (it) † 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
US6548550B1 (en) * 1999-08-06 2003-04-15 Innovet Italia S.R.L. Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field
JPWO2006077824A1 (ja) 2005-01-18 2008-08-07 国立大学法人京都大学 神経細胞再生のための医薬
ES2344920T3 (es) * 2006-03-28 2010-09-09 Epitech Group S.R.L. Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.
NZ552290A (en) * 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
CA2738117C (en) 2009-09-07 2016-12-06 Epitech Group S.R.L. Composition containing ultra-micronized palmitoyl-ethanolamide

Also Published As

Publication number Publication date
EP2796129A1 (en) 2014-10-29
US20130280333A1 (en) 2013-10-24
PL2796129T3 (pl) 2015-11-30
PT2796129E (pt) 2015-10-13
CY1116695T1 (el) 2017-03-15
ES2548190T3 (es) 2015-10-14
BRPI0919753B1 (pt) 2020-12-29
EP2475352B1 (en) 2015-06-17
ES2547133T3 (es) 2015-10-02
CY1116698T1 (el) 2017-03-15
AR115939A2 (es) 2021-03-17
CA2738117A1 (en) 2011-03-10
EP2796129B1 (en) 2015-06-17
BRPI0919753A2 (pt) 2015-12-08
ES2547133T5 (es) 2019-02-15
US20110171313A1 (en) 2011-07-14
CN102186459A (zh) 2011-09-14
EP2475352A1 (en) 2012-07-18
CA2738117C (en) 2016-12-06
US8470373B2 (en) 2013-06-25
JP2013503855A (ja) 2013-02-04
AU2009352080A1 (en) 2013-06-06
EP2475352B2 (en) 2018-09-05
PL2475352T3 (pl) 2016-01-29
WO2011027373A1 (en) 2011-03-10
BRPI0919753B8 (pt) 2021-05-25
JP5746178B2 (ja) 2015-07-08
CN106138022A (zh) 2016-11-23
PL2475352T5 (pl) 2019-02-28
US8663701B2 (en) 2014-03-04
ES2547133T9 (es) 2016-01-22
KR101662871B1 (ko) 2016-10-05
PT2475352E (pt) 2015-10-13
KR20120093861A (ko) 2012-08-23
AU2009352080B2 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
AR078159A1 (es) Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
NZ726746A (en) Stable cannabinoid formulations
CR20120623A (es) Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
GT201400111A (es) Triazolopiridinas sustituidas
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
UY32776A (es) Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
PE20140255A1 (es) Tableta dispersable en forma oral
CL2012002815A1 (es) Composicion para el cuidado bucal que comprende uno o mas compuesto de curcumina y una fuente de iones de zinc; correspondiente a 0.02 a 3% en peso de citrato de zinc; y uso de una fuente de iones de zinc para suprimir la degradacion y/o decoloracion del compuesto de curcumina en una composicion ara el cuidado bucal.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
BR112015005942A2 (pt) extratos de cynara scolymus, coffea spp. e olea europaea para tratamento de síndrome metabólica
BR112016015190A8 (pt) Composição farmacêutica livre de antioxidante e método de preparação da mesma
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos

Legal Events

Date Code Title Description
FC Refusal